Operator Profile
The Strategic Seller.
Planning an exit. The cage closes faster than you think.
You've built a career and a practice worth protecting. A buyer's QoE team will forensic every dollar of your EBITDA. The question isn't whether they'll find phantom earnings — it's whether you find them first.
What you're facing.
Valuation Gap
Your emotional attachment and the broker's preliminary number don't match what a QoE audit will actually validate. The "broker reality check" arrives when the buyer's team starts extracting your raw data.
Phantom EBITDA Exposure
Your reported profitability includes revenue that won't survive due diligence — provider-dependent production, unsanitized coding, hollow growth metrics. You don't know how much until someone extracts the raw numbers.
Timeline Trap
Most sellers start preparation 6–12 months before retirement. The window for meaningful EBITDA improvement is 18–36 months. Too late means you sell at the risk floor. Too early means extended burnout.
Legacy Anxiety
You built more than revenue — you built a culture, a team, a care philosophy. Deep fear that a new owner dismantles everything. This emotional obstacle prevents forward movement on an exit that's financially optimal.
The PDA 3-Factor Output — Exit Lens
The three numbers that determine your exit.
Your broker gives you one number. We give you three. The gap between them is the exact territory where millions of dollars in enterprise value are won or lost.
Premium Exit
Optimized EBITDA × Institutional Multiple
× 6x = $21M
Fully optimized operations, clean data chain, owner-independent systems. The number a PE buyer pays for an institutional asset.
Current EBITDA
As reported to your broker
× 6x = $15M
The number you and your broker believe. Before anyone extracts the raw data and rebuilds the P&L independently.
After QoE Audit
Current EBITDA − Phantom EBITDA
× 6x = $12.6M
What the buyer's QoE team actually validates. $400K in phantom EBITDA destroys $2.4M in enterprise value at a 6x multiple.
$8.4M in enterprise value separates the risk floor from the premium exit.
Our engagement takes you from $12.6M (what a buyer validates today) to $21M (what they pay after optimization). We then review the itemized quantification with you quarterly — watching the risk floor climb toward the premium exit in real dollars.
See how a Pre-LOI intervention generated $474K in additional annual revenue without adding patients: Case File 001: The Profitability Paradox →
How we engineer the premium exit.
Pre-LOI Forensic Extraction
We extract your raw data exactly the way a buyer's QoE team will — then present the findings to you first. No surprises at the table.
3-Factor Delivery + Phantom EBITDA Itemization
Every dollar of phantom EBITDA isolated by category: provider dependency, coding drift, PPO write-offs, hollow growth, scheduling leakage. You see exactly where the enterprise value is being destroyed.
Value Enhancement Roadmap
Prioritized plan to close the gap between risk floor and premium exit. Specific interventions ranked by EBITDA impact. Timeline aligned to your target exit window.
Quarterly Reviews Through Exit
Every quarter we re-extract, re-benchmark, and show the trajectory. When you're ready to go to market, the data chain is clean, the EBITDA is sanitized, and the narrative is yours — not the buyer's.
"Most founders go to market expecting a 10x platform valuation, unaware that their clinical data is fragmented. Buyers don't pay for clinical potential — they pay for auditable reality."
— James DeLuca
Frequently Asked Questions
What is phantom EBITDA and how does it affect my sale price?
+
Phantom EBITDA is the portion of your reported profitability that won't survive a buyer's Quality of Earnings audit. It includes provider-level coding drift, unsanitized PPO write-offs, owner-dependent revenue, and hollow growth anomalies. A practice reporting $2.5M EBITDA might only have $2.1M that's auditable — at a 6x multiple, that's $2.4M in lost enterprise value.
How far in advance should I start exit preparation?
+
Minimum 18 months before an LOI. The ideal window is 24–36 months. You need at minimum 18 months of clean, verifiable data before any buyer's QoE team examines your operations. If you wait until a buyer is at the table, you're already inside the 120-day exclusivity cage with no leverage.
My broker already gave me a valuation. Why do I need a 3-factor output?
+
Brokers typically value on a percentage of collections — a formula that doesn't account for phantom EBITDA, provider dependency, or data chain integrity. Our 3-factor output shows you three numbers: what a buyer will actually validate (risk floor), what the practice is worth today (baseline), and what it's worth with optimized operations (premium exit). The gap between the broker's number and the risk floor is your immediate exposure.
What happens during a Quality of Earnings audit?
+
The buyer's QoE team extracts your raw data — production, collections, expenses, patient records, provider schedules — and reconstructs your P&L independently. They're looking for restatements: revenue that's not recurring, expenses that are understated, EBITDA that's owner-dependent. Every discrepancy between your representations and their findings becomes a valuation haircut. We do this extraction first, so there are no surprises.
Can I preserve my practice culture and team through a sale?
+
Buyers pay more for practices with documented operational systems because documented systems are transferable. When your SOPs exist in a searchable office manual (we build these in NotebookLM), the buyer sees a practice that runs without the owner. That's attractive to institutional buyers AND to the team — because the playbook survives regardless of ownership. The best legacy protection is operational documentation.
What's the difference between selling to a DSO and selling to a PE-backed platform?
+
The valuation methodology differs significantly. DSOs typically offer collections-based multiples. PE-backed platforms value on EBITDA multiples — and they conduct rigorous QoE audits before closing. A practice with clean, auditable EBITDA and owner-independent operations commands a premium from institutional buyers that collections-based offers can't match. This is the thesis in Phantom EBITDA.
Buyers will forensic your data.
Beat them to it.
Related Intelligence